incretin mimetics (GLP-1 analogues) and incretin enhancers (DPP-4 inhibitors) are now available for the treatment of Type 2 diabetes. Initial combination therapy with a DPP-4 inhibitor ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Citing follow-up data for up to 10 years, the researchers noted that out of 12,351 patients on GLP-1s, only 278 developed dementia. In contrast, 1,849 on DPP-4 inhibitors and 2,480 on sulfonylurea ...

Patients who received GLP-1 RAs were compared to those who received dipeptidyl peptidase-4 (DPP-4) inhibitors; after propensity score matching, the final analysis included two cohorts of 168,428 ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Type 2 diabetes patients may have a lower risk ...

Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose ... to linagliptin if used in combination. Diuretics, steroids ...

The approval marks the second for a generic in this class of medications indicated to improve glycemic control in patients with type 2 diabetes as a complement to diet and exercise. The FDA today ...